Deal inked in October 2007 has a potential value of over $1 billion.

Galapagos received multiple €3.75 million, or $4.92 million, under its alliance with Janssen for rheumatoid arthritis therapeutics. The milestones are a result of preclinical proof-of-principle studies for compounds developed against Galapagos targets. 

The compounds demonstrated a reduction of an inflammatory disease biomarker in inflamed joint tissue cultured from collagen-induced arthritic mice.

In January 2008, Galapagos received its first milestone fee of E3.4 million. Galapagos obtained E15 million as an up-front payment in a deal that could be worth over $1 billion. Janssen gained rights to acquire small molecules from up to 12 of Galapagos’ internal programs involving rheumatoid arthritis therapeutic targets. 


Previous articleJ.P. Morgan Healthcare Conference—Tuesday, January 13 Update
Next articleVistaGen and Capsant to Develop Stem Cell Technology for Drug R&D